NewslettersHematopoiesis NewsHuman Immunology News NexImmune Sizes Up the Competition and Decides to Pause Myeloma T Cell Therapy Plans By Danielle Corrigan - August 16, 2022 0 Turns out NexImmune is not resistant to the tough competition in multiple myeloma. The company cited the competitive environment in the blood cancer space as reason for pausing enrollment on one of its two clinical candidates. [Fierce Biotech] Press Release